August 21, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy
 

Tokyo, Feb 15, 2013 (JCN) - Daiichi Sankyo will collaborate with a new company, Orphan Disease Treatment Institute, in the development of a treatment for Duchenne muscular dystrophy (DMD) with the active ingredient ENA oligonucleotide, a modified nucleic acid made using proprietary technology owned by Daiichi Sankyo.

Daiichi Sankyo is establishing the new company with Innovation Network Corporation of Japan (INCJ) and Mitsubishi UFJ Capital Co., Ltd. (MUC). INCJ will underwrite third party allocation of new shares for the new company with a maximum investment of 1.65 billion yen. The new company will also issue new shares by third party allocation for a fund managed by MUC.

Daiichi Sankyo will invest in the new company and mainly conduct development with the goal of achieving proof of concept (POC) for clinical drug development.

In 2006, professor Masafumi Matsuo (Kobe Gakuin University Department of Medical Rehabilitation) and designated professor Yasuhiro Takeshima (Kobe University Graduate School of Medicine Department of Pediatrics) were the first in the world to demonstrate the effectiveness of anti-sense oligonucleotides to restore dystrophin expression in DMD sufferers through the mechanism known as exon skipping.

Daiichi Sankyo and Orphan Disease Treatment Institute will jointly conduct clinical and non-clinical studies with the cooperation and support of these two professors with the aim of achieving POC.


By Jun Ota Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Daiichi Sankyo  News  
  Daiichi Sankyo Expands Collaborative Drug Discovery Program to Germany, Switzerland, and Austria  (Aug 1, 2013)
  Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy  (Feb 15, 2013)
  Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign  (Dec 20, 2012)
  Daiichi Sankyo, Ranbaxy Launch Psteoporosis Medication EVISTA in Romania  (Sept 2, 2009)
  Daiichi Sankyo Files Application for Dysuria Treatment KMD-3213 in China  (Jan 8, 2009)
  Daiichi Sankyo and Ranbaxy Move Forward Toward The Completion of the Landmark Deal  (Oct 20, 2008)
  Daiichi Sankyo's Tender Offer for Ranbaxy Ends in Success  (Oct 17, 2008)
  Shionogi to Acquire U.S. Drug Maker Sciele Pharma  (Sept 1, 2008)
  Daiichi Sankyo to Buy Indian Drug Giant Ranbaxy  (June 11, 2008)
  Daiichi Sankyo to Acquire German Biomedical Firm  (May 21, 2008)



 Recent  Drugs & OTC News   
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)
EIZO, Stryker to Partner in Monitor Management Systems for Operating Rooms (Oct 8, 2013)
HOYA to Invest in EndoMaster, for Robotic-assisted Surgical Systems (Aug 19, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)